The 340B rebate pilot was to have gone into effect on January 1. The American Hospital Association and other groups sued to ...

DHS appealed a Maine judge's ruling which stated that the federal government cannot start making changes to a drug discount ...

A federal judge in Maine has temproarily barred the Trump administration from implementing a new 340B drug rebate program for hospitals that was set to take effect on Jan. 1. The judge stated that the ...

By Patrick Demmer As a pastor and community advocate in Colorado, I have spent more than four decades walking alongside ...

A federal judge in Maine has put the brakes on a pilot program that would have enabled biopharma companies to offer rebates instead of discounts as part of the 340B program beginning Jan. 1, 2026.

(The Center Square) – Michigan hospitals are systematically exploiting a program for low-income patients, according to a new report. Released by Hospital Spending Watch, the report examined how ...

Too many hospitals take advantage of 340B, intended to make medications affordable for low-income patients. A New York proposal would make things worse. Credit: Getty Images. Millions of New Yorkers ...

NEW YORK--(BUSINESS WIRE)--Hercules Pharmaceuticals (Hercules), a national leader in pharmaceutical distribution, today announced that it has been approved as an authorized distributor in the 340B ...

Hercules Pharmaceuticals (Hercules), a national leader in pharmaceutical distribution, today announced that it has been approved as an authorized distributor in the 340B Prime Vendor Program ...

I am a proud health care professional here in Delaware, and I am calling on leaders in Washington, D.C. to support the 340B ACCESS Act. This legislation is urgently needed to restore accountability to ...

Hospitals across Michigan are exploiting a little-known federal program to squeeze millions of dollars from the state's poorest patients. Congress created the 340B Drug Pricing Program in 1992. It ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...